Gamma Vaccines

Gamma Vaccines is an Australian vaccine biotechnology company developing broad-spectrum vaccines against viral pathogens in human and animal health. Its lead program, GammaFlu, is designed as a cross-protective influenza vaccine intended to provide broader and longer-lasting immunity than conventional seasonal flu vaccines, with potential utility in pandemic preparedness. The company also lists programs targeting SARS-CoV-2, chikungunya, and Newcastle disease virus, and it is pursuing combination-vaccine applications using its inactivated whole-pathogen technology. Gamma Vaccines was founded in 2009 around university-originated intellectual property and remains an early-stage, private-to-public-unlisted company focused on preclinical development and partnering.